Effects of benazepril in the treatment of feline hypertrophic cardiomyopathy Results of a prospective, open-label, multicenter clinical trial

Journal of Veterinary Cardiology

Volumn 1, Issue 1, 1999, Pages 19-26

  Amberger, Christophe N ^a   Glardon, Olivier ^a   Glaus, Tony ^a   Hörauf, Angelika ^a   King, Jonathan N ^b   Schmidli, Heinz ^b   Schröter, Lutz ^a   Lombard, Christophe W ^a  

^a Swiss group of Cardiology   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DILTIAZEM; DILTIAZEM MEPHA RETARD; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; UNCLASSIFIED DRUG;

ADD ON THERAPY; AORTA ROOT; ARTICLE; CAT; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT ATRIUM; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE SEPTUM; HYPERTROPHIC CARDIOMYOPATHY; MALE; NONHUMAN; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SWITZERLAND; TREATMENT DURATION;

FELIDAE;

EID: 0002492720     PISSN: 17602734     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1760-2734(06)70026-1     Document Type: Article

References (24)

1. Amberger C., and Lombard C. Prevalence of cardiovascular disease in Switzerland. ESVC Newsletter 12 (1997) 10-11
2. Atkins C., Gallo A., Kurzmann I., and Cowen P. Risks factors, Clinical signs and survival in cats with a clinical diagnosis of idiopathic hypertrophic cardiomyopathy, 74 cases (1985-1989). J Am Vet Med Assoc 201 (1992) 613-618
3. Bright J., Golden A., Gompf R., Walker M., and Toal R. Evaluation of the calcium-channel blocking agents diltiazem and verapamil for treatment of feline hyper-trophic cardiomyopathy. J Vet Int Med 5 (1991) 272-282
4. Johnson L., Atkins C., Keene B., and Bai S. Pharmacokinetic and Pharmacodynamic Properties of conventional and CD-formulated Diltiazem in cats. J Vet Int Med 10 (1996) 316-320
5. Behrend E., Grauer G., Greco D., Rose B., and Thrall A. Comparison of the effects of Diltiazem and Aspirin on platelet aggregation in cats. J Am Anim Hosp Assoc 32 (1996) 11-18
6. Anfossi G., Mularoni E., Massuco P., et al. Calcium-channel blocking agent verapamil and diltiazem are inhibitors of vasopressin-induced human platelet activation. Clin Exp Pharmacol Physiol 11 (1991) 767-773
7. Maron B., Bonow R., Cannon III R., et al. Hypertrophic cardiomyopathy: Interrelations of clinical manifestations, pathophysiology and therapy. N Eng J Med 316 (1987) 78-786
8. Fox P., LIU S., and Maron B. Echographic assessment of spontaneous occurring feline HCM, an animal model of human disease. Circulation 92 (1995) 2645-2651
9. Bonagura J., Stepien R., and Lehmkuhl L. Acute effects of esmolol on left ventricular outflow obstruction in cats with hypertrophic cardiomyopathy: a Doppler echocardiographic study. J Vet Int Med 5 (1991) 123
10. Fox P. Evidence for or against efficacy of Beta-Blockers and Aspirin for management of feline Cardiomyopathies. Vet Clin N Am Small Anim Pract 21 (1991) 1011-1022
11. Kittleson M. CVT Update: Feline Hypertrophic cardiomyopathy. In: Bonagura (Ed). Kirk's Current Veterinary Therapy XII (1995), W.B. Saunders, Philadelphia, PA 854-862
12. Rush J., Freeman L., Brown D., and Smith F. The use of Enalapril in the treatment of feline hypertrophic cardiomyopathy. J Am Anim Hosp Assoc 34 (1998) 38-41
13. King J., Humbert-Droz E., and Maurer M. Pharmacokinetics of benazepril and inhibition of plasma ACE-activity in cats. Proceeding of 14th Am Coll Vet Int Med Forum (1996) 745
14. Spinale F., Holzgrefe H., Mukhewrjee R., et al. Angiotensin-Converting enzyme inhibition and the progression of congestive cardiomyopathy. Circulation 92 (1995) 2573-2581
15. Sun Y., Ratajska A., and Weber K. Inhibition of angiotensin-converting enzyme and attenuation of myocardial fibrosis by lisinopril in rats receiving angiotensin II. J Lab Clin Med 9 (1995) 95-101
16. Webb R., Miller D., Traina V., and Gomez H. Benazepril. Cardiovascular Drug Reviews 8 (1990) 89-104
17. Peterson E., and Moise S. Heterogeneity of Hypertrophy in Feline Hypertrophic Heart Disease. Journ. Vet. Int. Med. 7 (1993) 183-189
18. Maron B., and Spirito P. Implications of Left Ventricular Remodeling in Hypertrophic Cardiomyopathy. Am J Cardiol 81 (1998) 1339-1344
19. Liu S., Roberts W., and Maron B. Comparison of morphologic findings in spontaneously occurring cardiomyopathy in human, cats and dogs. Am J Cardiol 72 (1987) 944-951
20. Horning B., Arakawa N., and Drexler H. Effect of ACE-inhibition on endothelial dysfunction in patients with chronic heart failure. Eur Heart J 19 (1998) G48-G53
21. Pedersen H., Lorentzen K., and Kristensen B. Observer variation in the two-dimensional echocardiographic evaluation of mitral valve prolapse in dogs. Vet Radiol & Ultrasound 37 (1996) 367-372
22. Ladipo G., Dunn F., Prongle T., et al. Serial measurements of left ventricular dimensions by echocardiography. Assessment of week-to-week, inter- and intraobserver variability in normal subjects and patients with valvular heart disease. Br Heart J 44 (1980) 284-289
23. nd ed. (1999), WB Saunders, Philadelphia 321-358
24. Balcells E., Meng Q., Johnson W., et al. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 273 (1997) H1769-H1774